Section

Sun Pharma hits over 3 month low; slips 5% in strong market post Q4 results

By Business Standard - 6 months ago
The management guided for high single digit revenue growth in FY25 factoring in the impact of US site compliance issues.

Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.